Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), originally developed to treat type 2 diabetes, has emerged as a promising agent fo [...]
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), originally developed to treat type 2 diabetes, has emerged as a promising agent fo [...]